Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 4/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | PYGM | P11217 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11504437 | 0.84 | KMT2A (0.56) | PLA2G4BKMT2ATP53MAPTNR1H4 | |
| SCHEMBL29998681 | 0.84 | PTPN11 (0.67) | PTPN11PLA2G4BKMT2ATP53 | |
| SCHEMBL29091229 | 0.84 | PTPN11 (0.67) | PTPN11PLA2G4BKMT2ATP53 | |
| SCHEMBL16110081 | 0.83 | NR4A2 (0.60) | PYGLPYGM | |
| SCHEMBL21543820 | 0.80 | PTPN11 (0.62) | PTPN11PLA2G4BTP53ALDH1A1 | |
| SCHEMBL9075097 | 0.78 | KMT2A (0.58) | PTPN11PLA2G4BKMT2ATP53MAPT | |
| SCHEMBL8085899 | 0.77 | PTPN11 (0.68) | PTPN11PLA2G4BTP53 | |
| SCHEMBL16363711 | 0.76 | POLB (0.60) | KMT2ATP53ALDH1A1 | |
| SCHEMBL27968978 | 0.76 | FAAH (0.57) | PLA2G4BKMT2ATP53MAPTALDH1A1 | |
| SCHEMBL1750089 | 0.76 | THRB (0.60) | PTPN11PLA2G4BTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783529-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014160440-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | PTPN11 4385/4885PLA2G4B 2275/4885KMT2A 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.